Pfizer Ends Pact With GlycoMimetics After SCD Failure
Rivipansel’s Sickle Cell Disease Trial Failure Triggered Pfizer’s Move
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
